We have previously identified Ser293 in transmembrane segment 5 as a determinant for selective K Ca 2
Introduction
Small and intermediate conductance Ca 2ϩ -activated K ϩ channels (the KCNN family: K Ca 2.1, K Ca 2.2, K Ca 2.3, and K Ca 3.1) contain six transmembrane segments (S1-S6) arranged as a tetramer around a central pore. Each subunit associates with one calmodulin (CaM) molecule, acting as a ␤-subunit at the C-terminal CaM binding domain (CaMBD) (Xia et al., 1998; Khanna et al., 1999) . Ca 2ϩ binding to CaM rearranges the CaM/CaMBD region and the S6/S5 domains, thereby opening the channel. The nature of the gate remains elusive, but cysteine scanning experiments have confined its possible location to residues in the inner pore vestibule close to the selectivity filter. In contrast to K v channels, KCNN channels are assumed to exhibit "deep-pore gating" (Bruening-Wright et al., 2002 Klein et al., 2007; Garneau et al., 2009) , which is important for the understanding of the molecular pharmacology of positive and negative KCNN channel gating modifiers.
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-activated K ϩ channel; CaM, calmodulin; CaMBD, CaM binding domain; CNS, central nervous system; 1-EBIO, 1-ethyl-2-benzimidazolinone; UCL1684, 6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)-diquinolinacyclodecaphane; DCE-BIO, 5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one; NS4591, 4,5-dichloro-1,3-diethyl-2,3-dihydro-1H-1,3-benzodiazol-2-one; SKA-31, naphtho [1,2-d] thiazol-2-ylamine; NS8593, (R)-N-(benzimidazol-2-yl)-tetrahydro-1-naphtylamine; NS309, 6,7-dichloro-1H-indole-2,3-dione 3-oxime; GW542573X, 4-(2-methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester; B-TPMF, (N-{7-[1-(4-tert-butyl-phenoxy)ethyl]- [1, 2, 4] triazolo [1,5-a] pyrimidin-2-yl}-NЈ-methoxy-formamidine; ethyl]- [1, 2, 4] triazolo [1,5-a] pyrimidin-2-yl}-NЈ-methoxy-formamidine; 1-EBIO, 1-ethyl-2-benzimidazolinone; HEK, human embryonic kidney; I-V, current-voltage; phenyl)-3-pyridine carboxylic acid methyl ester; K Ca 2, small conductance Ca The K Ca 2 channel subtypes are widely and distinctly expressed in the CNS, controlling somatic excitability, pacemaker firing rates, and synaptic plasticity Pedarzani and Stocker, 2008) . Clinically used drugs with K Ca 2-activating properties are the centrally acting muscle relaxants zoxazolamine and chlorzoxazone, which are used for treating spasticity, and riluzole, which is registered for amyotrophic lateral sclerosis. The K Ca 2-facilitating properties (probably K Ca 2.2) of both chlorzoxazone and riluzole have recently been suggested to account for their beneficial effects in rodent ataxia models (Janahmadi et al., 2009; Alviñ a and Khodakhah, 2010) and in patients (Ristori et al., 2010) . K Ca 2 activation (probably K Ca 2.3) also arguably underlies reduced craving and dampening of excessive alcohol intake observed with chlorzoxazone in rats (Hopf et al., 2011) . Important hallmarks for a therapeutic K Ca 2-facilitating mechanism of these drugs are that 1-EBIO (1-ethyl-2-benzimidazolinone), the prototype KCNN channel activator, exerts a similar antiataxic action when applied locally into the cerebellum of tottering mice (Walter et al., 2006) and antiaddictive effect against alcohol when applied into rat nucleus accumbens core region (Hopf et al., 2010 ). In contrast, inhibition of K Ca 2 channels has not been demonstrated to account for clinical efficacy of any drug. The antidepressant fluoxetine is a weak blocker of cloned K Ca channels (Terstappen et al., 2003) and K Ca 2.3 channel block may mediate an antidepressant mechanism (Galeotti et al., 1999; Jacobsen et al., 2008) . However, it is doubtful whether this mechanism for fluoxetine plays a role compared with serotonin transporter inhibition.
Validation of specific K Ca channel subtypes as targets for CNS drug discovery is hampered by lack of selective and potent molecules that pass the blood-brain barrier. Classic K Ca 2 channel blockers such as UCL1684 [6,10-diaza-3(1,3) ,8(1,4)-dibenzena-1,5(1,4)-diquinolinacyclodecaphane] mimic the inhibition by the K Ca 2 selective peptide apamin and are unselective among the K Ca 2 subtypes. Like apamin, they further contain basic and charged moieties that limit their passage into the CNS. 1-EBIO and the K Ca 2-activating drugs are nonselective K Ca 2 enhancers and act more potently on K Ca 3.1. Unfortunately, this is also the case for the more potent positive modulators DCEBIO, NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime), 4,5-dichloro-1,3-diethyl-2,3-dihydro-1H-1,3-benzodiazol-2-one (NS4591), and SKA-31, even though these have emerged from dedicated chemical optimization programs (Wulff and Zhorov, 2008) .
Subtype-selective positive gating modulators and nonselective negative gating modulators have recently been identified. These have been instrumental in defining new sites and new modes of action for gating modulation of K Ca 2 channels. The negative gating modulator NS8593 [(R)-N-(benzimidazol-2-yl)-tetrahydro-1-naphtylamine] causes a reduction in the apparent Ca 2ϩ -sensitivity for channel activation (Strøbaek et al., 2006; Sørensen et al., 2008) . This effect depends on Ser507 and Ala532 (K Ca 2.3 numeration) positioned in the S5 pore helix and S6 transmembrane segment just below the selectivity filter and was therefore interpreted as NS8593 interaction with deeppore gating structures (Jenkins et al., 2011) . These amino acids are conserved among the K Ca 2 channels, thus explaining the lack of K Ca 2 subtype selectivity of NS8593 and close analogs (Sørensen et al., 2008) . The K Ca 2.1 selective activator GW542573X, which acts dually by directly opening the channel and by increasing the apparent Ca 2ϩ sensitivity (Hougaard et al., 2009) , depends on Ser293 in the S5 transmembrane helix, a K Ca 2.1-specific amino acid. These mixed effects differ significantly from the mode of action of nonselective activators but also from the K Ca 2.2/3 selective modulator cyclohexyl-[2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl]-amine, which increases the apparent Ca 2ϩ sensitivity via interaction with the C-terminal (Pedarzani et al., 2001; Hougaard et al., 2007; Li et al., 2009 
Materials and Methods
Chemistry. B-TPMF and CM-TPMF were purchased as racemates from Key Organics Ltd. (Camelford, Cornwall, UK). The compounds were resolved into their enantiomeric pairs by preparative chiral chromatography, using for B-TPMF a Chiracel OD-H column (solvent 40% ethanol in hexane; flow rate, 1.0 ml/min) and for CM-TPMF a Chiralpak AD-H column (solvent 40% ethanol in hexane; flow rate, 1.0 ml/min). Determination of chiral purity was performed on an analytical Waters Thar Investigator instrument equipped with a photodiode array detector: for B-TPMF using a Phenomenex (Torrance, CA) Lux2 column, 250 ϫ 4.6 mm, 5-m particle size (solvent super critical CO 2 with ethanol as cosolvent and isocratic elution with 45% cosolvent and a flow rate of 3.2 ml/min); for CM-TPMF using a Phenomenex Lux1 Column, 250 ϫ 4.6 mm, 5-m particle size (solvent super critical CO 2 with methanol as cosolvent and isocratic elution with 40% cosolvent and a flow rate of 3.2 ml/min). Chiral purity was determined by integration of the photodiode array (total absorbance) trace. Optical rotations were measured on a polarimeter (PerkinElmer Life and Analytical Sciences, Waltham, MA). Absolute configurations were not determined. NMR spectra were recorded on a Bruker UltraShield Plus 400 MHz (Avance II) instrument. Characterization of (Ϫ)-B-TPMF (C 19 Electrophysiology. Membrane currents were recorded using the whole-cell or the inside-out configuration of the patch-clamp technique. Cells seeded on cover slips were transferred to a 15-l recording chamber and continuously superfused at 1 ml/min. An integrated Ag/AgCl pellet electrode served as reference. Experiments were conducted at room temperature. Patch pipettes (approximately 2 M⍀) were pulled from borosilicate tubes with an outside diameter of 1.32 mm (Vitrex Medical, Herlev, Denmark) using a horizontal electrode puller (Zeitz Instruments, Augsburg, Germany). An electronically controlled micromanipulator (Eppendorf, Radiometer, Denmark) was used for the positioning of pipettes, and the experiments were controlled by an EPC-9 amplifier (HEKA, Lambrecht, Germany). Data were filtered at 3 kHz. Currents were elicited by applying a 200-ms linear voltage ramp from Ϫ80 to ϩ80 mV every 5 s from a holding potential of 0 mV. In whole-cell experiments, the cell capacitance and series resistance (R s below 8 M⍀, 80% compensation) were updated before each voltage ramp.
In all experiments a solution with a high K ϩ concentration was applied to the extracellular side of the membrane: 154 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 and 10 mM HEPES, pH adjusted to 7.4 with 1 M KOH. The intracellular solutions contained 154 mM KCl, 10 mM HEPES, 10 mM EGTA, or a combination of EGTA and NTA (10 mM in total). Concentrations of MgCl 2 and CaCl 2 required to obtain the desired free concentrations (Mg 2ϩ always 1 mM, Ca 2ϩ 0.01-10 M) were calculated (EqCal, Cambridge, UK) and added. In the nominally Ca 2ϩ -free intracellular solution, no Ca 2ϩ was added. The intracellular solutions were adjusted to pH 7.2 with 1 M KOH.
Calculations and Statistics. In inside-out experiments, EC 50 and IC 50 as well as Hill (n H ) values for compounds and Ca 2ϩ were estimated from equilibrium concentration-response relationships by fitting to the Hill equation. In whole-cell experiments, EC 50 values for current activation are not readily determined because of poor clamping conditions at higher degrees of channel activation. Instead, the concentrations of compound giving 100% current increase (called the SC 100 value; see Table 1 ) were estimated. In some experiments, K d values were calculated from single concentration applications by fitting to the kinetics of inhibition (Strøbaek et al., 2006) . All results are presented as the mean Ϯ S.E.M., with the number of experiments indicated. Significance testing was performed by Student's t test for unpaired samples.
Results
The chemical structures of the two new compounds, B-TPMF and CM-TPMF, as well as GW542573X, are shown in Fig. 1 . The effects of the isolated enantiomers of B-TPMF and CM-TPMF (see Chemistry above) were determined in wholecell voltage-clamp experiments by applying 10 nM concentrations of the compounds to HEK293 cells expressing human K Ca 2.1 channels. Representative current traces are shown in Fig. 2A , and the current recorded at Ϫ75 mV is plotted versus time in Fig. 2B . The (Ϫ)-enantiomer of B-TPMF inhibited the K Ca 2.1 current, whereas the (ϩ)-enantiomer had no effect. In contrast, (Ϫ)-CM-TPMF, induced a robust activation, again with the (ϩ)-enantiomer exerting no effect. The time course of this experiment (Fig. 2B ) underscores the reversibility of these actions, and the I-V curves show preservation of the normal inward rectification in presence of all compounds. Figure 2C summarizes this series of experiments and specifically documents that 10 nM (Ϫ)-B-TPMF significantly inhibits the K Ca 2.1 current, whereas (Ϫ)-CM-TPMF enhances it (p Ͻ 0.001, Student's t test for unpaired samples). The corresponding (ϩ)-enantiomers of both compounds, by contrast, are inactive at this concentration. Whole-cell experiments were also performed to quantify the enantiomer selectivity (experiments not illustrated; data in Table 1 ): K d values for (ϩ)-B-TPMF and (Ϫ)-B-TPMF were 1.6 Ϯ 0.5 M (n ϭ 5) and 15 Ϯ 7 nM (n ϭ 5), respectively. Likewise, (ϩ)-CM-TPMF activated K Ca 2.1 with an SC 100 of 200 Ϯ 44 nM (n ϭ 5) compared with 5 Ϯ 0.2 nM (n ϭ 6) for (Ϫ)-CM-TPMF. Thus, for B-TPMF and CM-TPMF, the activity on K Ca 2.1 channels resides primarily in the (Ϫ)-enantiomers, with enantiomer selectivities of ϳ100-and ϳ40 fold.
To investigate the subtype selectivity of the more active (Ϫ)-enantiomers, experiments were conducted on HEK293 cells stably expressing hK Ca 2.1, hK Ca 2.2, or hK Ca 2.3 channels (Fig. 3) . Because (Ϫ)-B-TPMF and (Ϫ)-CM-TPMF act equally well from both sides of the membrane, the inside-out configuration of the patch-clamp technique was chosen to achieve a well defined [Ca 2ϩ ] i . At a concentration of 30 nM, (Ϫ)-B-TPMF inhibited the K Ca 2.1 current by approximately 50%; conversely, (Ϫ)-CM-TPMF induced a 3-fold increase. At the same concentration, only minor effects were detectable on K Ca 2.2 and K Ca 2.3 ( Fig. 3A) , indicating that both compounds exhibit selectivity for K Ca 2.1 over the closely related isoforms. Full concentration-response relationships were obtained for the three K Ca 2 subtypes, and results for both compounds are summarized in Fig. 3 , B and C. The data generated for (Ϫ)-B-TPMF-induced inhibition conformed well to the Hill equation with an IC 50 value for K Ca 2.1 of approximately 30 nM and a complete inhibition of the current at 1 M, whereas K Ca 2.2 and K Ca 2.3 both were inhibited with IC 50 values around 1 M (see Table 2 , and Fig. 3  legend) . Hence (Ϫ)-B-TPMF is a selective inhibitor of K Ca 2.1, which displays approximately 30-fold selectivity over the (Table  1) . Table 3 also summarizes the effects of (Ϫ)-CM-TPMF and (Ϫ)-B-TPMF on more distantly related ion channels. Only marginal inhibitory effects were observed for both compounds at 10 M on members of other K ϩ channel gene families (K Ca 1.1, K v 7.2ϩK v 7.3, and K v 11.1) as well as Na v 1.2 channels. A broader selectivity profile was obtained for the two racemates by testing at concentrations of 10 M in the 69-receptor LeadProfilerScreen (internal reference number PT# 1107076) at MDSPharma (now Ricerca Biosciences LLC), Taiwan. Neither of the racemates reached the predefined significance criteria of Ͼ50% effect in any assay.
We next investigated the modes of action of (Ϫ)-CM-TPMF and (Ϫ)-B-TPMF. Classic enhancers of K Ca 2 channel activity increase the apparent Ca 2ϩ -sensitivity and are unable to activate the channels in the absence of intracellular Ca 2ϩ . In contrast, GW542573X (see Fig. 1 ), a recently described K Ca 2.1-selective compound, acts by a dual mechanism, increasing the apparent Ca 2ϩ sensitivity and inducing a small Ca 2ϩ -independent channel activation. Figure 4A shows the time course of an inside-out experiment in which the [Ca 2ϩ ] i was varied (0, 0.2, and 10 M) and the ability of 100 nM (Ϫ)-CM-TPMF to activate the K Ca 2.1 current at each Ca 2ϩ concentration was investigated. Figure 4B shows the corresponding I-V relationships. Addition of (Ϫ)-CM-TPMF clearly enhanced the K Ca 2.1 current in the nominal absence of Ca 2ϩ and shifted the I-V relationship from a small, nonspecific linear leak current to an inwardly rectifying current typical for K Ca 2 channels recorded under symmetrical K ϩ conditions. At an intermediate Ca 2ϩ concentration of 200 nM, where the K Ca 2.1 channels are partially Ca 2ϩ -activated, as well as at saturating Ca 2ϩ concentrations of 10 M, where the channels are maximally activated, application of (Ϫ)-CM-TPMF induced an increase in the current level. At all [Ca 2ϩ ] i , the current measured in the presence of (Ϫ)-CM-TPMF maintained the characteristic inward rectification. Figure 4C shows the Ca 2ϩ -response relationship of K Ca 2.1 in the absence of compound (Ctrl) as well as in the presence of 0.1 or 1 M (Ϫ)-CM-TPMF. It is noteworthy that (Ϫ)-CM-TPMF exerts a dual action on the K Ca 2.1 channel consisting of a leftward shift in the Ca 2ϩ -response curve (i.e., positive modulation) as well as a substantial direct activating effect, which is independent of Ca 2ϩ (close to 40% at low Ca 2ϩ and in the presence of 1 M (Ϫ)-CM-TPMF). Thus, from a mode-of-action perspective, (Ϫ)-CM-TPMF belongs to the GW542573X functional class of K Ca 2.1 activators. Viewed from a quantitative perspective, however, (Ϫ)-CM-TPMF is considerably more potent (Ͼ100 fold) than GW542573X, and the fraction of Ca 2ϩ -independent activation induced by the compound is much larger (ϳ40% versus 5%). K Ca 2 channels are inhibited by peptides such as apamin and scyllatoxin as well as by small molecules carrying positive charges mimicking the charges on apamin. These molecules bind from the outside, and despite the fact that an allosteric mode of action has been demonstrated for apamin (Lamy et al., 2010) , their inhibition is independent of the degree of channel activation by Ca 2ϩ . In contrast, negative gating modulators such as NS8593 interfere with the gating mechanism of K Ca 2 channels, causing reduced apparent affinity for Ca 2ϩ . A characteristic feature of this mode of action is potent inhibition at low [Ca 2ϩ ] i and reduced effect at higher Ca 2ϩ concentrations. The following experiment was designed to elucidate whether the inhibition by (Ϫ)-B-TPMF is dependent on the [Ca 2ϩ ] i . Figure 5A shows the time course of an inside-out experiment in which the ability of 30 nM (Ϫ)-B-TPMF to inhibit the K Ca 2.1 was evaluated at two different Ca 2ϩ concentrations: 0.3 M, equal to approximately 30% of maximal channel activity, and 10 M Ca 2ϩ , corresponding to maximal activity. (Ϫ)-B-TPMF inhibited approximately 75% of the current at the lower Ca 2ϩ concentration, whereas it inhibited only approximately 20% at 10 M Ca 2ϩ . In Fig. 5B , the degree of inhibition by 30 nM (Ϫ)-B-TPMF at three Ca 2ϩ concentrations (0.3-, 0.5-, and 10 M) is quantified. The effect is clearly dependent on the intracellular Ca 2ϩ concentration/channel activity, and (Ϫ)-B-TPMF accordingly fulfills the criteria for being a negative gating modulator.
Because of the very similar structures of (Ϫ)-B-TPMF and (Ϫ)-CM-TPMF, we envisioned that they might interact with a common binding site on K Ca 2.1. To test this hypothesis, we conducted a series of patch clamp experiments to elucidate possible competitive-like functional interactions. In the first series of experiments, we investigated whether K Ca 2.1 activated by different concentrations (1 and 10 M) of (Ϫ)-CM-TPMF would affect experimentally determined IC 50 values for (Ϫ)-B-TPMF. These concentrations of (Ϫ)-CM-TPMF were chosen because they both induce near-maximal activation of K Ca 2.1 (see Fig. 3C ) at a permissive fixed [Ca 2ϩ ] i of 200 nM. Figure 6A shows the I-V relations obtained in the presence of 1 M (left) and 10 M (right) of (Ϫ)-CM-TPMF. ] i in the absence of (Ϫ)-CM-TPMF is expected to be in the low nanomolar range (Fig. 5) . In the second series of experiments, we attempted to prove that the increase in IC 50 values in the presence of (Ϫ)-CM-TPMF is dependent of the presence of this compound per se rather than being an effect of the high open-state probability prevailing under the experimental conditions in Fig. 6 . Therefore, we compared the inhibition by (Ϫ)-B-TPMF at high [Ca 2ϩ ] i (10 M) with the inhibition at semimaximal [Ca 2ϩ ] i (0.5 M) in combination with 3 M (Ϫ)-CM-TPMF, resulting in similar degrees of activation (Fig. 7) . The time course of the experiment (Fig.  7A) shows that at 10 M Ca 2ϩ , (Ϫ)-B-TPMF (0.1 M) inhibits the current reversibly by 75%. However, after wash-out and reactivation with 0.5 M Ca 2ϩ ϩ 3 M (Ϫ)-CM-TPMF, no effect of 0.1 M (Ϫ)-B-TPMF was observed, and even a 100 times higher concentration was needed to get the same degree of inhibition as when the channel was similarly activated by Ca 2ϩ alone. Note also the strongly reduced rate of inhibition compared with the faster rate obtained at 0.1 M (Ϫ)-B-TPMF at the first addition. We conclude from these experiments that (Ϫ)-B-TPMF and (Ϫ)-CM-TPMF interact functionally on the K Ca 2.1 channel in a manner likely to reflect direct competition on a common binding site.
The action of both positive and negative modulators of K Ca 2 channels depend on very specific amino acid residues. 1-EBIO and cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methylpyrimidin-4-yl]-amine interact with the intracellular C-terminal CaMBD, whereas NS8593 depends on transmembrane amino acids. The K Ca 2.1-selective activator GW542573X acts via a single amino acid, Ser293, located in the S5 transmembrane region of K Ca 2.1. Because of the similar modes of action of GW542573X and (Ϫ)-CM-TPMF, we conducted a series of experiments to investigate the possible involvement of Ser293 in (Fig. 8B) but, on the other hand, significantly modulated the K Ca 2.3 L476S current level (Fig. 8C) . Full concentration-response relationships were generated for (Ϫ)-B-TPMF (Fig. 8D ) and (Ϫ)-CM-TPMF (Fig. 8E ) on K Ca 2.1 S293L and K Ca 2.3 L476S in excised inside-out patches. For comparison, the best fit curves for K Ca 2.1 and K Ca 2.3, obtained from Fig. 3 , are included as dotted lines. As seen from the figure, data obtained on K Ca 2.1 S293L was similar to those generated on K Ca 2.3, thus demonstrating full loss of sensitivity, both with respect to inhibition by (Ϫ)-B-TPMF and activation by (Ϫ)-CM-TPMF. Likewise, data obtained on K Ca 2.3 L476S was virtually identical to those on K Ca 2.1, demonstrating full gain of sensitivity of the K Ca 2.3 L476S construct for both compounds.
Discussion
We have described two structurally related compounds as new pharmacological modulators of Ca 2ϩ -activated K ϩ channels belonging to the KCNN gene family. Both are [1,2,4]triazolo[1,5-a]pyrimidines, a chemical series hitherto not described as having ion channel-modulating properties. Both (Ϫ)-CM-TPMF and (Ϫ)-B-TPMF potently modulated the K Ca 2.1 subtype but had considerably weaker activity on K Ca 2.2, K Ca 2.3, and K Ca 3.1. (Ϫ)-CM-TPMF is a mixed opener/ positive gating modulator, whereas the analog (Ϫ)-B-TPMF is a negative gating modulator. Coapplication experiments clearly revealed competition-like interactions between (Ϫ)-CM-TPMF and (Ϫ)-B-TPMF, and the high-affinity actions of both compounds were shown to depend critically on the Ser293 positioned in the S5 segment, as demonstrated by loss-ofsensitivity (K Ca 2.1 S293L ) as well as gain-of-sensitivity (K Ca 2.3 L476S ) mutations. CM-TPMF and B-TPMF are remarkably similar structurally, and the pharmacology leading to either positive or negative gating modulation is determined entirely by the substituents on the terminal phenyl ring, a 4-tert-butyl group in B-TPMF or 4-chloro-2-methyl substitution in CM-TPMF. We are currently further exploring the structural components leading to either activation or inhibition and the general structure-activity relationship associated with chemical modification within this compound class (Sørensen et al., 2010a,b,c) . It is noteworthy that for each of these compounds, the chirality introduced by the carbon atom in the linker separating the phenyl and the bicyclic heteroaromatic groups led to pairs consisting of a highly potent (Ϫ)-enantiomer and a 40-to 100-fold less active (ϩ)-isomer. Overall, we conclude that K Ca 2 channels-in particular the K Ca 2.1 isoform-possess a common high-affinity binding-site for (Ϫ)- [1, 2, 4] triazolo [1,5-a] ally influences the gating process in a facilitating or dampening way depending on minor changes in the substitution pattern of the interacting molecules. This is the first demonstration of a common site for both positive and negative pharmacological modulation of gating in K Ca channels, a phenomenon that is well established for the dihydropyridine pharmacology of L-type Ca 2ϩ channels [i.e., nifedipine versus S-(Ϫ)-1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-[trifluoromethyl] phenyl)-3-pyridine carboxylic acid methyl ester (Bay-k-8644) (Greenberg et al., 1984) ] as well as for the benzodiazepine pharmacology of GABA A receptors [i.e., diazepam versus methyl-6,7-dimethoxy-4-ethyl-␤-carboline-3-carboxylate (Sieghart, 1994) ].
It is interesting to compare the chemical structures of CM-TPMF/B-TPMF with the previously described (Hougaard et al., 2009 ) nonchiral and lower-potency K Ca 2.1 activator GW542573X (Fig. 1) , which also depends on Ser293 and has a qualitatively identical opener/positive modulator mode of action as described here for (Ϫ)-CM-TPMF. Both structural classes are relatively flexible, small molecules of similar sizes and molecular weights; both classes contain a terminal phenyl ring, although with different substitution pattern; and both GW542573X and the [1, 2, 4] triazolo [1,5-a] pyrimidines have a single potential hydrogen bond donating group and seven to eight hydrogen bond acceptors. Still, it is evident that GW542573X represents a structurally very different compound class containing two carbamate moieties of which one contains a terminal tert-butyl group also present in B-TPMF. Despite this apparent point of similarity, it should be noted that GW542573X is an activator, whereas a closer structure activity analysis comprising further structural analogs (not shown) revealed that the tert-butyl group is crucial for the effect of B-TPMF as an inhibitor. Overall, based on the structural differences described above and also the fact that the small structural difference arising from chirality has such detrimental effects on the pharmacology in CM-TPMF and B-TPMF, we consider it unlikely that the [1,2,4]triazolo[1,5-a]pyrimidines described herein would have exactly identical interaction points as GW542573X and share an identical binding site. Despite the parallels between GW542573X and (Ϫ)-CM-TPMF in terms of mode of action and interaction with Ser293, we therefore cannot exclude that it actually interacts with a site neighboring the A series of experiments exploring the apparent Ca 2ϩ affinity of rK Ca 2.2 through mutational analysis has demonstrated the complexity and the extended distribution of amino acids participating in or influencing the gating process in rK Ca 2.2 channels (Li and Aldrich, 2011) . Charged residues in S6 were found to form a ring of positivity near the inner pore mouth that causes intrinsic rectification but also influences the gating via an electrostatic mechanism, in particular by keeping the open-state probability very low at zero Ca 2ϩ . Charge reversal mutations of these amino acids strongly increase the open state probability at zero Ca 2ϩ and very significantly left-shift the Ca 2ϩ activation curve. Without in any way suggesting a common causality, these findings are phenomenologically very similar to the effects of (Ϫ)-CM-TPMF and GW542573X and serve to illustrate the point that amino acids in the transmembrane segments, far away from the CaM/CaMBD in the C terminus, are pivotally important for gating and determining apparent Ca 2ϩ affinity of K Ca 2 channels.
The physiological role of the K Ca 2.1 subtype remains obscure in contrast to the K Ca 2.2 and K Ca 2.3 subtypes, which, through their contribution to action potential afterhyperpolarizations and functional coupling with the NMDA receptor, are involved in controlling firing precision in pacemaking neurons and determining synaptic plasticity . K Ca 2.1 is predominantly expressed in the cortical/ limbic structures of the brain, a distribution overlapping to a large extent with the expression of K Ca 2.2, but is essentially absent from the basal ganglia and monoaminergic neurons, where K Ca 2.3 is the dominating subtype. It is noteworthy that K Ca 2.1 is also the KCNN subtype with the most specific CNS expression and seems confined to neurons (Rimini et al., 2000) . In contrast, the other KCNN members are also broadly expressed in the periphery on both neurons and somatic cell types, and K Ca 2.3 is also present on glia cells (Armstrong et al., 2005) . A serious obstacle toward exploration of the physiology of the K Ca 2.1 channel is the inability of the rat (and mouse) isoforms to express recombinantly in oocytes as well as mammalian cells. Furthermore, the phenotype of the K Ca 2.1 knockout mouse is still largely unknown, although it has been reported that the mAHP in CA1 is unaltered in these mice (Bond et al., 2004 ). An additional complication is the lack of subtype-selective tools targeting K Ca 2.1. In contrast to GW542573X, which is not very potent (EC 50 ϳ 7 M), both (Ϫ)-CM-TPMF and (Ϫ)-B-TPMF are high-potency K Ca 2.1 modulators (ϳ30 nM) that display acceptable selectivity over K Ca 2.2 and K Ca 2.3 and good to excellent selectivity over other ion channels and receptors. In particular, we foresee that the "package" of the two very close analogs with opposite effects on K Ca 2.1 may constitute a useful combination for many experimental situations: a detailed look at the concentration-response curves in Fig. 3 shows that (Ϫ)-CM-TPMF and (Ϫ)-B-TPMF can be applied up to 200 nM (causing 90% inhibition and 40% enhancement of K Ca 2.1) without significant functional activity on the other subtypes. (A note of caution: because of the Ca 2ϩ -dependent modulatory actions of both compounds, the corresponding percentages for natively expressed channels may deviate slightly). The reversibility properties of both compounds (Fig.  2 ) are also promising with respect to their use in a sequential manner on the same cell, at least in isolated neuronal preparations. We tentatively suggest that the opposite effects of (Ϫ)-CM-TPMF and (Ϫ)-B-TPMF on biological responses obtained from complex in vitro or in vivo biological systemspossibly combined with lack of effects of their respective (ϩ)-enantiomers-would be a strong indication of the participation of the K Ca 2.1 isoform in that particular process.
